news-med.jpg

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a ...

Topics: Corporate, Sanofi, Evotec, infectious diseases Read More

Evotec forms academic BRIDGE 'LAB591’ with Arix Bioscience and Fred Hutchinson Cancer Research Center

Combination of one of the premier cancer research centers with a strong company builder and Evotec's drug discovery expertise to create and support new companies focused on therapeutic breakthroughs for patients in the areas of oncology and infectious diseases Expands Evotec's academic ‘BRIDGE’ ...

Topics: Corporate, Evotec, Arix Bioscience, Fred Hutchinson Cancer Research Center Read More

Evotec and Celgene expand IPSC collaboration to include additional cell lines

$ 6 M payment to access additional cell lines

Topics: Corporate, Celgene, IPSC, Evotec Read More

Evotec and Celgene enter into strategic oncology partnership

Leveraging Evotec's phenotypic screening capabilities and compound libraries with an initial focus on solid tumours Upfront payment of $ 65 M, significant milestone payments and tiered royalties per programme

Topics: Corporate, Oncology, Celgene Read More

Evotec reports First Quarter 2018 results and provides Corporate update

55% increase in Group revenues Strong underlying operational performance with new business mix after Aptuit acquisition “3X30” outlook for 2018 confirmed Webcast and conference call today at 02.00 pm CEST

Topics: Corporate, first quarter update, 2018 results Read More

Evotec and Carna Biosciences collaborate on INDiGO platform

Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing ...

Topics: Corporate, INDiGO, Carna Biosciences, Blood cancer Read More

Evotec expands CRISPR-based technology offering with licence from ERS genomics

Hamburg, Germany, 02 May 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene ...

Topics: Corporate, genomics, technology, crispr Read More

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

Hamburg, Germany, 18 April 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive ...

Topics: Corporate, Bayer, Endometriosis, Phase I Read More

Evotec forms collaboration with Petra Pharma on INDiGO platform

Petra Pharma Corporation to harness Evotec's INDiGO platform to accelerate its lead programme (Petra-01 for oncology indications) through IND filing Evotec eligible to receive success-based milestones and research funding Evotec's INDiGO, a key value-driving component of its EVT Execute business ...

Topics: Corporate, INDiGO Read More

Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic

INDiGO® is the market leading integrated drug development solution that accelerates drug candidate delivery from candidate selection through to IND submission in typically less than 52 weeks.

Topics: Corporate, INDiGO Read More